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Abstract
Recent advances in the early detection and treatment of cancer have led to increasing numbers of cancer survivors world-
wide. Nonetheless, despite major improvements in the outcome of these patients, long-term side effects of radio- and
chemotherapy affect both patient survival and quality of life, independent of the oncological prognosis. Chemotherapy-re-
lated cardiac dysfunction is one of the most notorious short-term side effects of anticancer treatment, occurring in ~10%
of patients. Progression to overt heart failure carries a strikingly poor prognosis with a 2-year mortality rate of 60%.
Early detection of left ventricular damage by periodic monitoring and prompt initiation of heart failure treatment is key
in improving cardiovascular prognosis. To meet the growing demand for a specialised interdisciplinary approach for the
prevention and management of cardiovascular complications induced by cancer treatment, a new discipline termed car-
dio-oncology has evolved. However, an uniform, multidisciplinary approach is currently lacking in the Netherlands. This
overview provides an introduction and comprehensive summary of this emerging discipline and offers a practical strategy
for the outpatient management of this specific patient population.
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Introduction
Advances in the early detection and treatment of cancer
have led to increasing numbers of cancer survivors world-
wide [1, 2]. Nonetheless, despite this substantial progress,
long-term side effects of anticancer treatment can affect pa-
tient survival and quality of life considerably. Chemother-
apy-related cardiac dysfunction (CTRCD) is one of the
most notorious short-term side effects of anticancer treat-
ment, occurring in ~10% of patients [3]. To meet the grow-
ing demand for a specialised interdisciplinary approach for
the prevention and management of cardiovascular com-
plications, a new discipline termed cardio-oncology has
emerged since the late 1990s [4]. Cardiovascular toxicity
due to chemo- and radiotherapy manifests itself in many
other forms beyond myocardial dysfunction including, for
example, hypertension, arrhythmias and valvular and coro-
nary artery disease; these forms of toxicity fall outside the
scope of this review [5]. However, the main focus of this
overview is on the direct cardiotoxic effects of chemother-
apy on cardiomyocyte survival. In this article, we aim to
provide the clinical cardiologist, haematologists, and on-
cologists with an overview of this emerging discipline and
share our current knowledge regarding the practical imple-
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Table 1 Suggested further reading
Ref. no Author Year Topic Description
[6] Rochette 2015 Pathophysiology Cardiotoxic mechanisms of anthracyclines and trastuzumab
[7] Lenneman 2016 Pathophysiology Overview of most common anticancer treatments and their
mechanism of cardiotoxicity
[8] Moslehi 2016 Targeted cancer therapy Overview of cardiovascular toxicity of new targeted
(non-anthracycline) cancer therapies
[9] Curigliano 2012 Definitions/management ESMO oncology guidelines on cardiac monitoring, referral,
and therapy
[10] Christenson 2015 Early detection
Biomarkers
Overview of circulating biomarkers in predicting
chemotherapy-induced cardiac toxicity
[11] Thavendiranathan 2014 Early detection Echocardiogra-
phy
Echocardiographic myocardial deformation in the early
detection of cardiotoxicity
[12] Thavendiranathan 2013 Early detection
CMR
The role of cardiac magnetic resonance in the detection of
cardiotoxicity
[13] Plana 2014 Imaging ESC position paper on non-invasive imaging modalities in
cardio-oncology
[14] Herrmann 2014 Risk stratification and manage-
ment
Practical aspects regarding cardio-oncology care, including
an outline of a risk assessment tool
[15] Zamorano 2016 Risk stratification and manage-
ment
ESC position paper on cancer treatments and cardiovascular
toxicity
[16] Lancellotti 2013 Radiotherapy Consensus paper on imaging and management of cardiovas-
cular complications of radiotherapy
[5] Naaktgeboren 2017 Long-term outcome Overview on long-term outcome after anticancer treatment
(chemo- and radiotherapy)
[17] Dalen 2011 Prevention Cochrane review on cardioprotective interventions for can-
cer patients receiving anthracyclines
[18] Kalam 2013 Prevention Systematic review on cardioprotective therapy for preven-
tion of cardiotoxicity with chemotherapy
[19] Johnson 2017 Training Paper exploring training programs for medical specialists in
cardio-oncology
mentation of risk stratification, screening, and treatment of
CTRCD. Suggested further reading on the following topics,
as well as those that fall outside the scope of this overview,
are summarised in Tab. 1.
Scope of the problem
The incidence of CTRCD is determined by multiple fac-
tors, of which the most important involve the adminis-
tered chemotherapeutic agent(s) and, in the case of an-
thracyclines, the cumulative dose. Additionally, specific pa-
tient characteristics have been shown to be associated with
a higher risk of CTRCD. Anthracyclines and trastuzumab
(Herceptin) are among the most widely prescribed agents
associated with serious cardiotoxicity.
Anthracyclines (e.g. doxorubicin) are a cornerstone in
the treatment of numerous haematological and solid malig-
nancies. In a large meta-analysis pooling data from 18 stud-
ies involving a total of almost 50,000 patients undergoing
treatment with anthracyclines, the incidence of clinically
overt and subclinical cardiotoxicity was reported in 6.3%
(3.2–9.3%) and 17.9% (11.6–24.2%) of patients respec-
tively [20]. End-stage heart failure was observed in 2–4%
of patients and carries a strikingly poor prognosis, with a 2-
year mortality rate of up to 60% [21, 22].
Several attempts have been undertaken to reduce the in-
cidence of anthracycline-induced cardiotoxicity. A dose-de-
pendent relationship with heart failure led to restrictions in
the administered cumulative dose. Other initiatives have in-
volved the generation of numerous anthracycline analogues
(e.g. epirubicin), concomitant administration of cardiopro-
tective drugs (e.g. dexrazoxane), liposomal drug formula-
tions, the application of prolonged infusion regimens to
reduce peak plasma dose, and consecutive administration
of other cardiotoxic drugs (i. e. trastuzumab), since simul-
taneous administration dramatically increases CTRCD in-
cidence [18, 23–28]. Nevertheless, due to fear of impaired
antitumour efficacy, the implementation of several of the
above-mentioned preventive actions has been limited in
clinical practice. Hence, anthracycline-related cardiotoxi-
city still remains a significant clinical problem [29].
Trastuzumab is administered in breast cancer patients
with human epidermal growth factor receptor 2 (HER2)
positive tumours [30]. A meta-analysis found an overall
incidence of a left ventricular ejection fraction (LVEF)
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Table 2 Cardiotoxicity Risk Score (CRS)
Medication-related riska Examplesb
High (risk score 4) Anthracyclines; trastuzumab; cyclophosphamide; 5-fluorouracil
Intermediate (risk score 2) Pertuzumab; vinblastine; capecitabine; ponatinib
Low (risk score 1) Bevacizumab; imatinib
Rare (risk score 0) Carboplatin; fludarabine; paclitaxel; rituximab
Patient-related risk factors (1 point per item)
– Cardiomyopathy or heart failure
– Coronary artery disease or equivalent (including peripheral artery disease)
– Hypertension
– Diabetes mellitus
– Prior or concurrent anthracyclines
– Prior or concurrent chest irradiation
– Age <15 years or >65 years
– Female gender











aThe highest medication-related risk score (e. g. 4, 2, 1 or 0) is used for calculation of the CRS
bSee the supplementary table for each separate agent and/or regime. Adapted from: [14]
decline in 11.2% of patients (RR 1.83, 90% CI 1.36–2.47)
[31]. Importantly, the prognosis of trastuzumab-induced
cardiotoxicity is generally more favourable when compared
to anthracycline-induced cardiotoxicity, with a recovery of
LVEF after timely cessation of trastuzumab administration
in a majority of patients [32].
Definition
Multiple definitions of CTRCD have been proposed in the
literature to date, although a consensus is currently still
lacking [33]. The most widely adapted definition is a de-
crease in LVEF of more than 10 percentage points to a value
below the lower limit of normal, irrespective of symptoms.
The American Society of Echocardiography and the Euro-
pean Association of Cardiovascular Imaging (EACVI) de-
fine an LVEF of 53% on echocardiography as the lower
limit of normal [13]. Subclinical CTRCD is defined as
a global longitudinal strain (GLS) with >15% relative re-
duction from baseline with preservation of LVEF [13]. Un-
fortunately, this definition does not cover other signs of
cardiotoxicity, such as the detection of cardiac troponin re-
lease.
Pathophysiology
The pathophysiological mechanisms leading to CTRCD
are complex, incompletely elucidated, and differ among
chemotherapeutic agents [7, 8]. Traditionally, for agents
that have a direct effect on cardiomyocytes, two types of
cardiotoxicity have been proposed [24].
Type I cardiotoxicity is characterised by irreversible
damage and related to the cumulative administered dose.
Anthracyclines are most well-known for their associa-
tion with type I cardiotoxicity. Mechanisms believed to
play a role in this type of cardiotoxicity are multifactorial
and involve (1) the generation of excess reactive oxygen
species, (2) accumulation of toxic anthracycline metabolites
that interfere with calcium handling and thereby disrupt
sarcomere structure and function, (3) interaction with tran-
scription factor topoisomerase-2β, and (4) mitochondrial
dysfunction [6, 34, 35].
Type II cardiac damage is believed to cause temporary,
reversible dysfunction in a dose-independent manner [32].
Trastuzumab is a classical type II agent, which binds to the
HER2 receptor and thereby inhibits downstream associated
signalling cascades. It is conceivable that the inhibition of
these pathways plays a central role in trastuzumab-associ-
ated cardiotoxicity, but the exact mechanism still remains
to be discovered [36].
Although the subdivision into type I and type II car-
diotoxicity is arbitrary, as persistent LV dysfunction has
also been observed in patients treated solely with type II
agents, this subdivision is nevertheless still widely applied
[37].
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Risk stratification
Cardiovascular management of patients receiving car-
diotoxic treatment is based on the timely recognition of
those at high risk of developing CTRCD. Accurate risk
stratification is crucial to enable an effective pre-selection
of patients that should be referred to a cardio-oncological
team prior to, or in an early phase of, anticancer treatment.
Treatment-related risk factors
Not all chemotherapeutic agents are (equally) cardiotoxic,
as shown in Supplementary Table 1. In this table, we sub-
divided a subset of the most commonly used chemothera-
peutic agents into four categories, based on the incidence
of LV dysfunction reported in the literature (group 1: <1%,
group 2: 1–5%, group 3: 5–10% and group 4: >10%). It
should be noted that the applied definition of LV dysfunc-
tion varies between the studies, and that the incidence is an
approximation of risk.
One of the most important risk factors for CTRCD in
agents that cause type I cardiotoxicity is the administered
dose. In patients that require more intensive regimens or
have a history of previous malignancy for which they were
treated with type I agents, it is important to take the cu-
mulative dose into consideration. However, some patients
develop CTRCD even with doses far below the maximum
cumulative dose [23]. Therefore, a tolerated and ‘safe’ dose
seems to be highly dependent on the presence of patient-
related risk factors.
Patient-related risk factors
Patient-related risk factors that have been identified thus far
include female gender, black race, exposure to cardiotoxic
drugs at a young or old age (<15 and >65 years), pre-
vious or concomitant chest radiation therapy, obesity and
classical cardiovascular risk factors including hypertension
and diabetes mellitus [15, 20, 38]. Having ≥3 of these risk
factors has been associated with a 5–6 times higher risk
of cardiotoxic side effects compared to patients without
any risk factors [20]. Nonetheless, in the absence of all
these known determinants, some patients still develop se-
vere CTRCD, indicating that unknown factors contribute to
individual susceptibility. It is conceivable that the individ-
ual genetic profile plays a considerable role in modulating
individual risk [39].
Risk predictionmodels
A few risk prediction models have been published in the lit-
erature thus far [14, 40, 41]. The Cardiotoxicity Risk Score
(CRS) proposed by the Mayo Clinic takes both patient and
treatment risk factors into account (Tab. 2; [14]). This model
addresses the a priori risk of developing CTRCD. Patients
with a CRS score of ≥4 could benefit from cardiological
consultation during and after chemotherapeutic treatment,
and those with high risk scores should be closely monitored
during and after treatment. However, this risk model, as well
as the other models, has not been validated in a prospective
setting and its real clinical value remains to be determined.
In the absence of validation, the European Society of Car-
diology (ESC) therefore currently does not advise the use
of a particular model in the position paper on cancer treat-
ments and cardiovascular toxicity released in 2016 [15].
Instead, the committee stresses the importance of clinical
judgement in individual risk assessment, which includes
clinical history, physical examination and evaluation of car-
diac function pre-chemotherapy.
Early detection of myocardial damage
Circulating biomarkers
Due to the minimal invasiveness, limited costs, and low
inter-observer variability, biomarkers constitute an appeal-
ing approach to aid in the early detection of subclinical
cardiotoxicity (Fig. 1). Most studies have assessed the po-
tential of classical cardiac biomarkers, i. e. cardiac troponin
(cTn) and N-terminal pro-B-type natriuretric peptide (NT-
proBNP) [10]. Troponins seem to be the most promising
candidates, both in patients treated with anthracyclines and
various agents used for targeted-therapy (e.g. trastuzumab)
[10, 42]. Nevertheless, repeated sampling is currently nec-
essary to detect cTn elevations, as the optimal timing to
reach maximal sensitivity has not yet been established [42].
Multiple-gated acquisition scan
Since the 1970s the mainstay imaging modality for the
screening and monitoring of cardiac function in oncology
patients has been the multiple-gated acquisition scan [43].
Unfortunately, the only measurement that can be derived
from these scans is the LVEF, which is less sensitive for
early detection of CTRCD. Another important concern is
the radiation exposure (~5–10mSv/scan) in patients under-
going serial assessments. For example, the Dutch Guide-
lines for Breast Cancer recommend that patients receiving
trastuzumab therapy should undergo cardiac evaluation to
determine the LVEF before the start of treatment and sub-
sequently once every 3 months during treatment [44]. The
cumulative radiation exposure in patients treated with this
agent for 1 year thereby equals ~25–50mSv, which is com-
parable to 250–500 chest radiographs or 4–8CT angiogra-
phy procedures.
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Fig. 1 Time frame of detection
and treatment of cardiotoxicity.
Early initiation of heart failure
treatment (green, blue line) leads
to better outcomes regarding re-
covery of contractile function.
Initiation of heart failure treat-
ment at time when symptoms are
present (red line) results in poor
outcomes regarding recovery of
cardiac function. cTn Cardiac
troponin, CTRCD chemothera-
py-related cardiac dysfunction,
NYHA New York Heart Associa-
tion classification
Fig. 2 Echocardiographic deformation imaging. Longitudinal follow-up of a 51-year-old female with breast cancer with a high cardiovascular
risk (Cardiotoxicity Risk Score 7: female, hypertension, concurrent anthracyclines, and high-risk agent trastuzumab). After the initial 4× AC
(adriamycin-cyclophosphamide) there was a significant decrease of >15% in global longitudinal strain (GLS) with preservation of left ventric-
ular ejection fraction (LVEF). During the trastuzumab treatment there was a subsequent decrease in LVEF of >10%. After interruption of the
trastuzumab treatment, the LVEF showed a complete recovery
(Strain) echocardiography
Echocardiography is the most suitable imaging modality
for the evaluation of patients in preparation for, during, and
after cancer therapy, because of its wide availability, easy
repeatability, versatility, lack of radiation exposure, and
safety in patients with concomitant renal disease. Further-
more, echocardiography allows a comprehensive evaluation
of most cardiac structures and multiple parameters besides
the LVEF. It has been recommended as the first line screen-
ing tool to assess cardiac function in this specific patient
population [13]. In particular, the measurement of LVEF
by 3D echocardiography has been shown to be feasible and
accurate with an error of <5% (compared to a 10% varia-
tion in biplane LVEF calculation) [45]. Echocardiographi-
cally derived GLS calculates the systolic deformation of the
myocardium by a commercially available speckle tracking
algorithm (Fig. 2; [46]). This parameter reflects contractile
function and is well validated in healthy subjects and in
a variety of myocardial disease states. The GLS has been
shown to be the single best parameter to predict CTRCD, as
a decrease of this parameter is often seen before a relevant
reduction of LVEF is observed [11].
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Fig. 3 a–c Cardiac magnetic resonance imaging. Cardiac magnetic resonance imaging with T1 mapping in a female breast cancer survivor, treated
with anthracyclines. Extracellular volume fraction (ECV) is a non-invasive measurement of diffuse myocardial fibrosis and can be calculated from
the haematocrit; pre-contrast (a), post-contrast (b) T1 maps. In this patient, the ECV map (c) reveals diffuse elevated ECV values up to 42%
(normal is <28%), in particular in the septal segments, reflecting widespread myocardial fibrosis after anthracycline exposure
Cardiac magnetic resonance
Cardiac magnetic resonance (CMR) is considered the ref-
erence standard for the assessment of ventricular function
[47]. Due to its superiority in myocardial tissue character-
isation, CMR is suitable to detect early tissue damage fol-
lowing chemotherapy. Early changes in tissue composition
include myocardial oedema with an increase in LV mass, in-
flammation, and decrease in myocardial strain [12]. Within
months after initiation of therapy LV end-systolic volume
increases, and with T1 mapping techniques diffuse intersti-
tial fibrosis, a hallmark of anthracycline-induced cardiotoxi-
city, can be detected and quantified (Fig. 3a–c). The absence
of focal fibrotic lesions results in a lack of late gadolin-
ium enhancement, although contrast-enhanced CMR can
be used to exclude other causes of myocardial dysfunction
in these patients, such as myocardial infarction. Although
unique insights can be obtained with MRI, due to costs and
availability CMR is presently not suitable as the first-line
imaging technique for regular follow-up imaging.
Therapeutic interventions
With the exclusion of cancer patients in all high-impact
heart failure intervention randomised controlled trials re-
garding the efficacy of, for example, ACE inhibitors and
beta-blockers, the response rate of patients with CTRCD to
conventional heart failure therapy has not been thoroughly
investigated and evidence-based decision-making on opti-
mal treatment is lacking [48].
In a single-centre study by Cardinale et al. (n= 215),
treatment response in patients with a decline of LVEF to
45% was highly dependent on the timing of treatment
initiation [49]. The response rate was the highest (64% re-
sponders) among patients with CTRCD that received heart
failure treatment <2 months after detection of LV impair-
ment and decreased to only 7% after 4–6 months. Remark-
ably, no response was observed in patients with CTRCD
that received treatment ≥6 months after the last chemother-
apeutic cycle (Fig. 4a). Hence, detecting the development
of CRTCD as soon as possible guides the optimal timing of
treatment initiation, since this seems to be particularly cru-
cial for treatment response. However, in a follow-up study
by the same group, a large proportion of patients did not
show recovery of cardiac function despite early initiation of
conventional heart failure treatment. Only 11% showed full
recovery to a mean LVEF of 61%. Cardiac function was
partially restored in 71% of the patients, to a mean LVEF
of 54%. Notably, 18% of patients did not respond to treat-
ment, with a mean LVEF at the end of the study of 38%
(Fig. 4b; [3]). Cardiac outcome for partial and non-respon-
ders is significantly worse, including heart failure requiring
hospitalisation and cardiac-related death (Fig. 4c; [49]).
Currently, the only practice guidelines on the manage-
ment of cardiovascular toxicity induced by anticancer treat-
ment have been released by the European Society of Med-
ical Oncology (ESMO) [9]. Guidelines from the ESC and
the American Heart Association are still lacking, albeit the
ESC recently released the first position paper on cancer
treatments and cardiovascular toxicity [15].
The evidence for the use of cardioprotective agents to
counteract LVEF decline in patients treated with anthracy-
clines is marginal, with the exception of dexrazoxane [17,
50]. Cardioprotective agents to prevent trastuzumab-related
cardiotoxicity are largely unexplored. The results of the first
randomised controlled trials investigating the cardioprotec-
tive effect of candesartan and carvedilol were recently pub-
lished, showing no protection against LVEF decline [51].
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Fig. 4 a–c Response and outcome to heart failure (HF) treatment in
patients with chemotherapy-related cardiac dysfunction. a Percentage
of (partial) responders according to the time elapsed from diagnos-
ing left ventricular dysfunction and start of HF therapy. b Left ven-
tricular ejection fraction in patients with cardiotoxicity and with no
(square/red), partial (triangle/blue) or full (dot/green) recovery fol-
lowing heart failure therapy. c Cumulative cardiac event rate during
follow-up. Reprinted from: [3, 49]. CT Chemotherapy
Roadmap towards outpatientmanagement
Collaboration between the Departments of Cardiology,
Radiology, Haematology and Oncology resulted in a spe-
cialised cardio-oncology healthcare pathway, which was
launched at the University Medical Centre Utrecht, the
Netherlands early in 2015. The aim of this initiative is to
improve cardiac outcome in oncology patients by (1) iden-
tifying patients at high risk of developing CTRCD before
chemotherapeutic treatment is initiated, (2) screen and mon-
itor high-risk patients to enable early detection of (subclin-
ical) cardiac dysfunction which (3) facilitates early treat-
ment initiation in order to improve overall cardiovascular
outcome. Patients are monitored up to 1 year after the end
of chemotherapy, as a majority of the patients described in
the literature develop CTRCD within this time frame [3]. It
should be noted that long-term follow-up data in these pa-
tients are scarce. Our in-house protocol is delineated below
(Fig. 5).
Registration procedure
Patients are referred by the oncologist/haematologist based
on in-hospital protocols on cardio-oncology referral. Main
indications for referral are planned treatment with car-
diotoxic agents, cardiac evaluation before (autologous or
allogenic) stem-cell transplantation (SCT), or patients pre-
senting with complaints suggestive of underlying cardiac
disease (e.g. heart failure, ischaemia, or arrhythmias). The
baseline risk is determined based on the Cardiotoxicity Risk
Score (CRS) (Tab. 2). This risk score has been slightly ad-
justed from its initial publication [14] regarding the risk
attributed to the different chemotherapeutic agents (see
Supplementary table). Albeit this risk model has not been
prospectively validated, we have chosen to incorporate it
in our in-house protocol to ensure objective and uniform
risk assessment and limit inter-physician variability. All
patients pre-SCT as well as high-risk patients (CRS≥ 4)
that will have to undergo treatment with cardiotoxic agents
are seen at our cardio-oncology outpatient clinic. Child-
hood cancer survivors and ex-Hodgkin patients are referred
to the LATER and BETER [Dutch for ‘better’] outpatient
clinic respectively [52].
Initial cardiac evaluation
Preferentially, the first cardiac evaluation is performed be-
fore chemotherapeutic treatment is initiated. This first as-
sessment involves exploration of the cardiac and onco-
logical history (including a detailed assessment of known
cardiovascular risk factors as well as past and planned
chemotherapeutic regimens), physical examination, labora-
tory analysis (including kidney function, NT-proBNP and
cTn), and an ECG. Furthermore, a complete echocardio-
graphic evaluation is performed to determine cardiac di-
mensions, valvular function, LVEF (preferably 3D), GLS,
diastolic function, right ventricular (RV) function and RV
systolic pressure. Reference values can be obtained from
the current EACVI guidelines [13]. In short, an LVEF of
>53% on 2D/3D echocardiography and a GLS of –19.7%
(–20.4% to –18.9%) are considered normal.
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Fig. 5 Cardio-oncology care at the University Medical Centre Utrecht, The Netherlands. AC Anthracyclines; BNP brain natriuretic peptide;
CMR cardiac magnetic resonance; CRS Cardiotoxicity Risk Score; CTRCD chemotherapy-related cardiac dysfunction; GLS global longitudinal
strain; LVEF left ventricular ejection fraction; SCT stem-cell transplantation. *To be considered, depending on local policy
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Individual follow-up
The interval of follow-up for patients who are treated with
agents associated with type I cardiotoxicity is determined
by the baseline CRS (Fig. 5). The follow-up duration at
the cardio-oncology clinic is typically up to 1 year after
the last cycle of chemotherapy. After this period, further
cardiac assessment takes place at the BETER outpatient
clinic if the patient is found to be eligible [52]. Patients
treated with trastuzumab are seen pre-chemotherapy, once
every 3 months during treatment, and 1 year after the end of
treatment. In asymptomatic patients that develop subclini-
cal CTRCD, the monitoring interval is intensified as these
subjects are at high risk for developing heart failure.
Additional examinations
CMR is recommended in patients with clinical CTRCD
and can be considered in patients with subclinical CTRCD.
Measurements include LVEF, RVEF, delayed enhance-
ment imaging, T1rho-mapping, and determination of GLS.
Ischaemia detection using adenosine stress imaging is per-
formed if there is a history of coronary artery disease,
suspected ischaemia, or ≥2 cardiovascular risk factor(s)
(smoking, diabetes, hypertension, hypercholesterolaemia
and a positive family history) in men >40 years and
post-menopausal women. Patients with severe CTRCD
(LVEF< 45%) or a positive family history for cardiomy-
opathies are offered a referral for genetic counselling as
part of our local policy, as genetic variants in cardiomyopa-
thy-associated genes may have predisposed these patients
to CTRCD [53, 54].
Management of patients with CTRCD
Multidisciplinary meetings attended by the cardio-oncol-
ogist and oncologist/haematologist take place to discuss
cases with (subclinical) CTRCD. At these meetings, the
effect of modification(s) to the chemotherapeutic regimen
to decrease cardiovascular toxicity is weighed against the
consequences of these alterations for the oncological prog-
nosis. Furthermore, in patients that have LV dysfunction
prior to the initiation of cancer treatment, the optimal treat-
ment regimen is chosen through shared decision-making.
Type I cardiacdysfunction In patients with clinical CTRCD,
treatment with ACE inhibition (preferentially enalapril) and
a beta-blocker (preferentially carvedilol) is indicated. In
patients with contraindications for ACE inhibition, an an-
giotensin-receptor blocker can be considered. Patients that
show signs/symptoms of congestion receive loop diuret-
ics. These recommendations are based on two single-centre
studies [3, 49]. The value of other agents or the optimal
dose are currently unknown. At the moment, there is no ev-
idence that treatment with other heart failure drugs (e.g. al-
dosterone antagonists) has any added value.
Type II cardiac dysfunction Upon development of type II
cardiac dysfunction, the causal chemotherapeutic agent(s)
should be discontinued immediately. After 3–4 weeks, the
LVEF and GLS are re-assessed. If LV function has re-
covered, a re-challenge with the same chemotherapeutic
agent(s) can be attempted under strict cardiological moni-
toring. Even though there are currently no evidence-based
recommendations for heart failure medication in patients
with this type of cardiotoxicity, treatment according to the
ESC and ESMO guidelines should be considered if there
is a persistent decline in LVEF and signs/symptoms of de-
compensation [9, 48].
Subclinical cardiac dysfunction At this point in time, there
is no evidence that initiation of heart failure medication
in patients with subclinical cardiac dysfunction improves
outcome. To prevent unnecessary treatment, we have de-
cided to wait with initiation of heart failure treatment until
the patient develops signs of clinical CTRCD, during the
intensified follow-up.
Future perspectives
Despite the advantages in our understanding of this specific
heart-failure entity with regard to the underlying pathophys-
iological mechanisms, improving diagnostic accuracy, and
implementation of specific therapeutic interventions, there
are still several unresolved issues and challenges within the
field of cardio-oncology. To detect opportunities for im-
provement at this moment in time, the routinely provided
cardiovascular care in oncology patients prior to the cardio-
oncology era has to be investigated. This includes the fre-
quency at which baseline cardiac function is assessed, the
incidence of cardiovascular complications, referral patterns,
treatment initiation- and response. We acknowledge that the
(adjusted) CRS is probably insufficient to accurately iden-
tify high-risk patients. Development of sophisticated algo-
rithms, which can be applied in the clinical field, will be
an important focus of future trials and registries in order to
optimise resources and pursue a cost-effective health care
system. Risk stratification models need prospective vali-
dation and further improvement by the identification of
additional (genetic) risk factors. Furthermore, personalised
chemotherapeutic regimens, with their increasing complex-
ity, go hand in hand with the need to establish interactions
between agents and the combined effect on the cardiovas-
cular system. Early detection of subclinical cardiac damage
and dysfunction seems essential to optimise the treatment
530 Neth Heart J (2018) 26:521–532
Table 3 Ongoing clinical trials on the treatment of cardiotoxicity
Location NCT number Title Intervention Start date










USA NCT02096588 Detection and Prevention of Anthracycline-Related
Cardiac Toxicity with Concurrent Simvastatin
Simvastatin or
placebo
May 2014 Active, not
recruiting
Canada NCT03186404 Statins for the Primary Prevention of Heart Failure
in Patients Receiving Anthracycline Pilot Study
Atorvastatin or
placebo
July 2017 Not yet re-
cruiting
UK NCT03265574 PROACT: Can We Prevent Chemotherapy-Related
Heart Damage in Patients with Breast Cancer?








USA NCT02177175 Carvedilol for the Prevention of Anthracycline/
Anti-HER2 Therapy Associated Cardiotoxicity
among Women with HER2-Positive Breast Cancer
Using Myocardial Strain Imaging for Early Risk
Stratification
Carvedilol or placebo June 2014 Active, not
recruiting
Brazil NCT01724450 Carvedilol Effect in Preventing Chemotherapy-In-
duced Cardiotoxicity
Carvedilol or placebo June 2012 Recruiting
USA NCT02717507 Carvedilol in Preventing Heart Failure in Childhood
Cancer Survivors
Carvedilol or placebo April 2016 Recruiting
USA NCT01347970 Pharmacologic Reversal of Ventricular Remodeling
in Childhood Cancer Survivors at Risk for Conges-
tive Heart Failure (PREVENT-CHF): A Phase IIB
Randomized Placebo-Controlled Trial
Carvedilol or placebo May 2012 Active, not
recruiting
Italy NCT02236806 Cardiotoxicity Prevention in Breast Cancer Patients












USA NCT01009918 Lisinopril or Coreg CR® in Reducing Side Ef-




March 2010 Active, not
recruiting
response rate; therefore, suitable biomarkers as well as the
timing of biomarker sampling and echocardiographic mon-
itoring need to be investigated. Ongoing therapeutic trials
(Tab. 3) will shed more light on the potential of conven-
tional heart failure treatment in this population as well as
the optimal timing of treatment initiation. The establishing
of specialised cardio-oncology units across the Netherlands
will speed the development of this field, optimising the cost-
benefit ratio of chemotherapeutic treatment with the poten-
tial to improve both oncological and cardiac outcome [19,
55]. Furthermore, we will launch the ONCOR prospective
multicentre registry in the near future, in which we aim
to collect information on patients visiting cardio-oncology
units across the Netherlands. Information from this registry
will enable further national and international studies to im-
prove the prognosis of this patient population.
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